Recombinant Activated Factor VII for Prevention of Bleeding Unrelated to Hemophilia: Clinical and Economic Systematic Review

CADTH’s health technology assessment report examines the clinical efficacy and cost-effectiveness of off-label use of recombinant activated factor VII (rFVIIa), an agent currently approved to control bleeding in patients with either hemophilia A or B and clotting factor inhibitors.  

Report

This report has been extensively peer-reviewed by external clinical and methodological experts.

Summaries